Home » Case Studies » Commercial Strategic Planning » Biosimilar Differentiation Str…

Biosimilar Differentiation Strategy

CBPartners developed a strategy to drive differentiation of a biosimilar through service offerings and contracting in Canada and select LatAm and MEA countries.

Objectives

Identify service offerings and / or contracting that can drive differentiation and preference of BIOSIMILAR A versus the originator biologic and other biosimilars.

Scope

Methodology

Internal working session with the local and regional team to vet hypotheses, followed by a semi-qual / quant primary research program moderated in local language with n=185 stakeholders, including key opinion leaders (KOLs), physicians, nurses, hospital administrators and payers.

Deliverables

  • Catalogue of value-added services and contracts offered by the originator biologic across market segments.
  • Biosimilar defence strategies implemented by the manufacturer of the originator biologic.
  • Stakeholder influence map outlining formal and informal leverage points to drive biosimilar uptake.
  • Service offering and contracting expectations for biosimilars and impact on biosimilar differentiation.
  • Strategic recommendations to drive differentiation of BIOSIMILAR A.

Illustrative Outputs

Impact

CBPartners developed a strategy to drive differentiation of a biosimilar through service offerings and contracting.